ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences

WALTHAM, Mass. -- (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

• 14^th Annual BIO CEO & Investor Conference
  3:00 pm on February 14, 2012 in New York, NY
  Presenter: Daniel Junius, President and CEO

• 2012 RBC Capital Markets’ Healthcare Conference
  1:30 pm on February 29, 2012 in New York, NY
  Presenter: Gregory Perry, Executive Vice President and CFO

The webcast of each presentation can be accessed live through the “Investor Information” section of the Company’s website, www.immunogen.com; a replay of each presentation will be available at the same location for one week.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's Targeted Antibody Payload (TAP) technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are now numerous TAP compounds in clinical development with a wealth of clinical data reported. ImmunoGen’s collaborative partners include Amgen, Bayer HealthCare Pharmaceuticals, Biotest, Lilly, Novartis, Roche, and Sanofi. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.